Enhancer of zeste homolog 2 (EZH2) is aberrantly expressed or mutated in multiple types of cancer cells and plays an oncogenic role in tumorigenesis and development in most cancers. Results from pilot clinical studies have implied that EZH2 inhibitors have therapeutic potential against some cancers. However, the exact mechanisms by which EZH2 plays oncogenic roles and EZH2 inhibition exerts anticancer effects are incompletely understood. To date, the findings of studies focusing on EZH2 and cancer cells have failed to fully explain the observations in preclinical and clinical studies. Therefore, recent studies about the roles of EZH2 in cancers have shifted from cancer cells to immune cells. The human immune system is a complex network comprising multiple subpopulations of immune cells. Immune cells communicate and interact with cancer cells during cancer development and treatment, dictating the fate of cancer cells. Elucidating the roles of EZH2 in immune cells, especially in cancer patients, promises the identification of novel immunotherapeutic strategies or priming of existing immunotherapies against cancer. Hence, we reviewed the studies focusing on the involvement of EZH2 in various immune cells, aiming to provide ideas for immunotherapies targeting EZH2 in immune cells.

中文翻译：

---

EZH2在免疫细胞中的功能：新型免疫疗法的原则

zeste 同系物 2 (EZH2) 增强子在多种类型的癌细胞中异常表达或突变，并在大多数癌症的肿瘤发生和发展中发挥致癌作用。初步临床研究的结果表明 EZH2 抑制剂对某些癌症具有治疗潜力。然而，EZH2 发挥致癌作用和 EZH2 抑制发挥抗癌作用的确切机制尚不完全清楚。迄今为止，针对 EZH2 和癌细胞的研究结果未能完全解释临床前和临床研究中的观察结果。因此，最近关于 EZH2 在癌症中的作用的研究已经从癌细胞转移到免疫细胞。人体免疫系统是一个复杂的网络，由多个免疫细胞亚群组成。在癌症发展和治疗过程中，免疫细胞与癌细胞交流和相互作用，决定着癌细胞的命运。阐明 EZH2 在免疫细胞中的作用，尤其是在癌症患者中，有望确定新的免疫治疗策略或启动现有的针对癌症的免疫治疗。因此，我们回顾了侧重于 EZH2 参与各种免疫细胞的研究，旨在为针对免疫细胞中 EZH2 的免疫疗法提供思路。